Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

#24-80 eBlitz Group AB receives observation status

eBlitz Group AB ("the Company"), whose shares are listed on Nordic SME, published a press release on August 26, declaring that the Company has entered a letter of intent to acquire 100% of the shares in Healthy to 100 AS. According to the Rules for issuers whose shares are listed on Nordic SME (“the Rulebook”), a company's shares can be placed under observation if the Company is planning, or has undergone, such a significant change of operations or organization that the Company can be perceived as being a new enterprise. With reference to situation the above, Nordic Growth Market NGM

Hexagon Composites ASA: Share capital increase registered

26 August 2024: Reference is made to the stock exchange announcement by Hexagon Composites ASA (the "Company") on 20 August 2024 regarding the issue of 8,450,704 new shares upon completion of a private placement of shares. The share capital increase pertaining to the issuance of the new shares under the private placement has now been registered with the Norwegian Register of Business Enterprises. The Company's new registered share capital is NOK 21,007,041.60 divided into 210,070,416 shares, each with a nominal value of NOK 0.10 per share. For more information: Ingrid Aarsnes, VP ESG &

Spermosens passes an important milestone receiving approval for significant clinical study.

Spermosens AB announces that the Swedish Ethical Review Authority has given approval for the company’s application to start a clinical study at Reproductive Medicine Center (RMC) in Malmö with JUNO-Checked to evaluate sperm quality for couples undergoing fertility treatment. This means that the company now takes the next step in validating diagnostic use of JUNO-Checked.Spermosens recently announced a revised strategy to accelerate the development and commercialisation of the unique JUNO-Checked product designed to address male infertility, with a clinical study conducted at RMC as a

New policy statement guides Finnfund's investment activities in strengthening natural values and biodiversity

Development financier and impact investor Finnfund has adopted a policy statement that brings together the guiding principles and goals based on which Finnfund strives to strengthen the well-being and diversity of nature and to mitigate possible nature and biodiversity risks in its investment activities. The policy statement recognises biodiversity loss as a significant threat to the well-being of the planet and the sustainable development of societies and the economy. Companies and investors can actively protect and strengthen biodiversity through their own activities. Correspondingly,

SmartCraft ASA (SMCRT) – Reminder: Invitation to presentation of second quarter 2024 results

26 August 2024 - SmartCraft ASA will publish its second quarter 2024 financial report on Tuesday 27 August 2024 at 07:00 CET together with the Q2 2024 presentation material on the company website and www.newsweb.no. Investors, analysts, and journalists are welcome to join to an English language webcast presentation of the report on the same day, Tuesday 27 August 2024, at 08:00 CET. Webcast link: https://channel.royalcast.com/landingpage/hegnarmedia/20240827_2 Presenters: · Chief Executive Officer Gustav Line · Chief Financial Officer Kjartan Bø Viewers are welcome to

Acquisitions of own shares in Evolution AB (publ)

Evolution AB (publ) (“Evolution”) has, during the period 19 August - 23 August acquired a total of 378,546 own shares within the framework of the repurchase programme introduced by the board of directors to improve the capital structure of Evolution by reducing the capital, and thereby creating added shareholder value.The repurchase programme, which Evolution announced on 18 July 2024, is being implemented in accordance with the EU Market Abuse Regulation No 596/2014 (“MAR”) and Commission Delegated Regulation No 2016/1052 (“Safe Harbour Regulation”). During the period 19 August - 23

Buyback of Class B shares in Essity during week 34, 2024

Between August 19, 2024, and August 23 2024, Essity Aktiebolag (publ) repurchased a total of 270,000 own Class B shares (ISIN: SE0009922164) under the framework of the buyback program as resolved by the Board of Directors.The share purchase is part of the SEK 3bn buyback program announced by Essity on June 17, 2024. The buyback program will extend from June 17, 2024, until the 2025 Annual General Meeting and be implemented in accordance with the EU Market Abuse Regulation (MAR) and the European Commission’s Delegated Regulation 2016/1052 (Safe Harbour Regulation). The share repurchase is

SOFTSWISS Throws Hollywood Party to Celebrate 15th Anniversary

SOFTSWISS , a global tech provider of innovative iGaming solutions, is set to celebrate its 15th anniversary in grand style with an exclusive Hollywood-themed party.As SOFTSWISS marks 15 years of success in iGaming, the company is gearing up to host a spectacular evening of Hollywood luxury and glamour. It will serve as the culmination of a year-long series of anniversary celebrations. The event will take place on 24 September in Lisbon, a fresh location for the industry and a new home for the SBC

Gaming Innovation Group completes acquisition of Titan - Strengthening SEO and content services

Gaming Innovation Group Inc. (“GiG”), a leading force in digital marketing and media for the online gaming industry, has today successfully acquired Titan Inc. Limited (“Titan”), following the head-of-terms agreement signed in June, see announcement from GiG on 17 June 2024. Titan is a top-tier provider of SEO and content services, and this strategic move bolsters GiG’s operational capabilities and reinforces its market leadership within Gentoo Media (formerly GiG Media), its thriving media and affiliate business. The integration of Titan will drive cost savings and operational

Integrum AB: Invitation to the First Quarter 2024/25 Results Presentation

Mölndal, Sweden – August 26, 2024 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) will host a webcast presentation of its first quarter 2024/25 results on August 29, 2024 at 14:00 CEST.Integrum’s CEO Rickard Brånemark will present the report together with CFO Jörgen Svanström and US President Jeffrey Zanni in a webcast. The presentation will be held in English. Time: Thursday, August 29, 2024 at 14:00 CEST. Location: Webcast (see link below). The report will be available at https://integrum.se/investor-relations/financial-reports-calendar/ The webcast and

Bridging borders at World Water Week 2024

Many obstacles exist to a peaceful and sustainable future. How can we better understand these obstacles and each other? And how can water help us bridge borders and be a key to a more peaceful and sustainable future?World Water Week 2024 officially opens today in Stockholm, Sweden, and online. The conference comes in the face of an increasingly apparent water crisis. It focuses on how collaboration can help us address not only water issues, but also how we can – by collaborating around water – address many other of the world’s most urgent challenges. Disturbances to the planet’s water

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 185 – 26 AUGUST 2024   In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 171/24 and 173/24, respectively. Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Martin Badsted, Chief Financial Officer, tel.: +45 33 42 05 26, e-mail: mba@norden.com

UPM receives platinum in the EcoVadis responsibility assessment

(UPM, Helsinki, 26 August 2024 at 11:00 EEST) – EcoVadis has awarded UPM a platinum score based on the company’s sustainability performance in four categories: Environment, Labour and Human Rights, Ethics and Sustainable Procurement. Only one percent of the 130,000 global companies assessed received a platinum rating. UPM scored 81/100 in the Manufacture of Pulp, Paper, and Paperboard industry. “The feedback from Ecovadis, both on strengths and areas of improvement, is extremely valuable and helps us to continuously improve our sustainability performance,” says Sami Lundgren, Vice

BioStock: Q2 marked continued progress for Medivir in advanced liver cancer

At the ESMO GI congress in June, Medivir presented greatly improved results for patients with advanced liver cancer in the ongoing phase Ib/IIa study with fostrox in combination with Lenvima. The company is increasingly optimistic about the possibility of launching the first approved drug treatment after first-line treatment of the disease. This is evident from Medivir’s interim report.– We are now looking forward to presenting detailed and mature clinical data from the study with fostrox at the ESMO Cancer Congress in Barcelona in September, says CEO Jens Lindberg.Read the full article

Dampskibsselskabet NORDEN A/S – weekly report on share buy-back

ANNOUNCEMENT NO. 184 – 26 AUGUST 2024   On 9 August 2024, NORDEN initiated a share buy-back programme in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buy-back programme runs from 9 August 2024 up to and including no later than 23 October 2024. For details, please see announcement no. 171 of 8 August 2024.   Under the share buy-back programme, NORDEN will purchase shares for up to a total of USD 14 million (approximately DKK 95 million).

BioStock: Lipum recruits new CMO – “I have been following their research for a while and am impressed”

In preparation for the continued clinical development of SOL-116 in rheumatoid arthritis, Lipum has strengthened its management team by appointing Peter Hovstadius as the new Chief Medical Officer. Peter brings extensive experience in clinical drug development from leading roles at companies such as XNK Therapeutics, Novartis, and MSD.– It is important for me to work in an organisation that not only has great ideas but also the capacity to turn those ideas into reality, and always with the patient in mind, says Peter in an interview.Read the full article at biostock.se 

DecideAct strengthens its growth opportunities in the US and Canada by achieving SOC2 type II security certification

The SOC 2 type II certification supports DecideAct's growth ambitions in the US and Canadian markets by providing comprehensive benefits that improve trust, compliance, security, operational efficiency, and competitive positioning. Thus, it is a strategic investment that can facilitate market entry, customer acquisition, and long-term growth.Many organizations in the US and Canada, especially those in regulated industries like finance, healthcare, and technology, require their service providers to have SOC 2 certification. For a SaaS company like DecideAct with growth ambitions in the US

Careium launches SaaS alarm management and IoT platform i-Care Center, securing MD Medicus as the first external customer

Careium, a European champion in technology enabled care, announces the launch of i-Care Center, a unique end-to-end SaaS platform for management of alarms, sensors and IoT solutions for seniors, enabling rich, safe, and active lives via the Careium ecosystem. The first customer, MD Medicus, is a leading player within medical and care services, based in Germany with a genuinely global footprint. MD Medicus serves more than 60,000 connected seniors with its care services, and in addition provides care and healthcare support via its insurance partners to 20 million people worldwide. The

BioStock: Abliva's CEO – We are the leading programme in mitochondrial disease

Abliva is developing drugs for the treatment of mitochondrial diseases, and the company posted positive interim phase II data with its lead candidate KL1333 this summer. Abliva’s CEO Ellen Donnelly stopped by the BioStock Studio to discuss the results and how they impact Abliva's development moving forward.Watch the interview with Abliva ’s CEO Ellen Donnelly at biostock.se: Abliva's CEO: We are the leading programme in mitochondrial disease - BioStock  This is a

OBSERVE MEDICAL ASA: Mandatory notification of trade – grant of share options to primary insider

Oslo, 26 August 2024 Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) has today granted 1,000,000 share options to primary insider and CEO of the Company, Jørgen Mann. Each share option gives the right to purchase one share in the Company. The share options will vest over a period of two years. 1/3 of the share options vested today on the award date, 1/3 of the share options will vest on the first anniversary of the award date and 1/3 of the share options will vest on the second anniversary of the award date. The share options will be exercisable during

Repurchase of Truecaller B shares in week 34, 2024

During 19 August 2024 and 23 August 2024 Truecaller AB (publ) (LEI code 549300TEYF1FA5G5GK26) has repurchased in total 180,000 own B shares (ISIN: SE0016787071) as part of the share buyback programme initiated by the board of directors.The share buybacks form part of the share buyback programme announced by Truecaller on 28 May 2024. The share buyback programme will run between 28 May up until the 2025 AGM which will be held in May 2025, and is carried out in accordance “Emittentregelverket”. On the Annual General Meeting 2024 the Board was authorized to buy back B-shares up until the

Dicot informs about last day for subscription of units in ongoing rights issue

Uppsala, Sweden, August 26, 2024. Friday August 30, 2024, is the last day for subscription in Dicot Pharma's ongoing rights issue of units of approximately SEK 122.6 million (the "Rights Issue"). Please note that some banks and nominees have an earlier date for subscription deadlines. Holders of unit rights should therefore check with their bank or nominee whether they use an earlier closing date for subscription. The last day of trading in unit rights on Spotlight Stock Market is August 27, 2024.NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED

There are no items matching the current filter
There are no more items matching the current filter
Back to top